W0180 + pembrolizumab

W0180 + pembrolizumab is an investigational combination therapy composed of two monoclonal antibodies: W0180, which targets the **VISTA receptor (V-domain Ig suppressor of T-cell activation)** as an immune checkpoint inhibitor, and pembrolizumab, an approved **PD-1 (programmed death-1) pathway inhibitor**. W0180 is designed to enhance anti-tumor immunity by blocking VISTA-mediated immunosuppression, while pembrolizumab reinvigorates T-cell responses by blocking PD-1. This combination aims to amplify immune-mediated anti-tumor activity in patients with advanced or metastatic solid tumors, particularly those unresponsive to standard immunotherapies. W0180 is developed by Pierre Fabre, and pembrolizumab is developed and manufactured by Merck. The combination is being tested in early-phase clinical studies for solid tumors, especially cases that do not respond to conventional treatments[1][3].

Other names

pembrolizumab